How does Tylvalosin tartrate achieve both antibacterial and antiviral effects?

Tylvalosin tartrate, also known as acetylisovaleryl tylosin tartrate, is a third-generation veterinary sixteen-membered ring macrolide raw material. The industrial product is usually a light yellow-white crystalline powder. Based on the tylosin core, it is modified by acetylation and isovalerylation before forming a salt with tartaric acid. It retains the antibacterial properties of classic macrolides and also has the unique ability to accumulate intracellularly and regulate the intracellular environment. It is a core raw material in the livestock and poultry breeding field that can prevent secondary infections of mycoplasma, Gram-positive bacteria and PRRS-related viruses. It is used extensively in the formulation of livestock and poultry premixes and water-soluble powders. It is also a standard raw material for veterinary pharmacological calibration and drug resistance evaluation.

⚛️Modification and optimization of physicochemical and transmembrane properties

The main body of tylosin tartrate retains the sixteen-membered macrocyclic lactone cyclic skeleton of tylosin. Acetyl and isovaleryl groups are added to the side chains of the tylosin glycocycle. The addition of these two hydrophobic side chains directly alters the overall lipid-water partition coefficient of the molecule, significantly enhancing its ability to penetrate bacterial and animal macrophage membranes. Subsequently, it combines with one molecule of tartaric acid in an acid-base salt formation. The polar carboxyl structure of tartaric acid compensates for the insufficient water solubility of the modified molecule, ultimately forming a pharmaceutically suitable salt structure with excellent stability.

The complete molecule possesses multiple chiral carbon atoms, with a cyclic lactone ring maintaining its overall spatial configuration. Two glycosyl structures, deoxyaminosaccharide and mycosaccharide, are responsible for site-specific binding to bacterial ribosomes. The externally modified acetyl and isovaleryl side chains weaken molecular polarity, avoiding the inherent defects of primary tylosin, such as susceptibility to gastric acid degradation and weak tissue penetration. Under normal temperature and dry storage conditions, the finished product exhibits stable physicochemical properties; in humid environments, only slight surface clumping occurs. Prolonged storage at high temperatures may lead to slow hydrolysis of the lactone ring, resulting in reduced efficacy.

 

In terms of solubility, the tartrate structure improves water solubility, making it readily soluble in purified water, methanol, and ethanol systems, slightly soluble in acetone, and almost insoluble in nonpolar alkane organic solvents. Industrial purification utilizes recrystallization to remove synthetic byproducts and incompletely acylated tylosin intermediates. The purified product has a stable effective content that meets pharmacopoeia control standards. Heavy metal and residual solvent parameters match the veterinary drug raw material access regulations of various countries, making it suitable for both water-soluble formulations and feed premixes.

 

The core advantage of this molecule lies in the dual modification of the acyl side chain and tartaric acid salt formation. The hydrophobic side chain ensures efficient intracellular penetration, while the hydrophilic tartaric acid group ensures rapid dissolution and absorption in the digestive tract of livestock and poultry after oral administration. These two structural modifications synergistically result in a significantly higher oral bioavailability than the original tylosin, and also lay the structural foundation for the drug's large-scale accumulation in alveolar macrophages.

 

The molecule is metabolized in animals to produce the active metabolite 3-O-acetyltylosin. This derivative also retains its complete antibacterial structure, enabling it to exert its antibacterial effect continuously in vivo, indirectly extending the overall in vivo efficacy period of the raw material and reducing the cost burden on livestock due to the frequency of continuous administration.

🎯Achieving antibacterial and antiviral regulation through a dual pathway

Tylvalosin tartrate first pathway of action focuses on inhibiting bacterial protein synthesis. After penetrating the cell membrane of susceptible bacteria, the drug binds specifically to the 23S rRNA site corresponding to the 50S subunit of the bacterial ribosome, blocking the transpeptidation and translocation processes during the ribosomal peptide chain elongation phase. This prevents bacteria from synthesizing structural proteins and functional enzymes, thus continuously inhibiting bacterial proliferation. This binding mode is highly specific to susceptible bacteria such as Mycoplasma, Staphylococcus, and Clostridium, and has no affinity for mammalian somatic cell ribosomes. At conventional therapeutic doses, it does not damage the protein synthesis process of livestock and poultry cells.

 

The drug, relying on its modified side chains for strong lipophilicity, penetrates the alveolar macrophage membrane and remains largely intracellularly, achieving concentrations dozens of times higher than the corresponding blood drug concentrations. Its slightly alkaline molecular properties gradually fine-tune the lysosomal pH environment within macrophages. Since PRRS virus replication relies entirely on an acidic lysosomal environment, this change in intracellular pH directly disrupts viral membrane fusion and gene replication, inhibiting viral proliferation at the host cell level. This unique mechanism is a pharmacological characteristic not found in first-generation macrolide drugs.

 

Along with the adjustment of the intracellular environment, the drug simultaneously regulates the NF-κB inflammatory signaling pathway, inhibiting the excessive release of pro-inflammatory mediators such as interleukins and chemokines, alleviating inflammatory exudation and pulmonary edema caused by lung infection. While controlling the pathogen, it also reduces respiratory damage in livestock and poultry, improves feed intake and respiratory status, and reduces the probability of secondary mortality in severe cases.

 

Targeting intracellular parasitic pathogens like *Lawsonia intracellularis*, this drug, with its high intracellular accumulation properties, directly enters the host's intestinal epithelial cells, continuously interfering with bacterial protein synthesis and interrupting the colonization and proliferation of proliferative ileitis pathogens within intestinal cells. This differs from most antibacterial raw materials that only exert their effects outside the cells.

 

With the synergistic effect of multiple pharmacological actions, the raw material can directly suppress sensitive pathogens and improve virus-induced immunosuppression and inflammatory damage, achieving simultaneous antibacterial, virulence-controlling, and anti-inflammatory pharmacological effects. This is the key reason for its routine use in pig farms with high incidence of porcine reproductive and respiratory syndrome (PRRS).

🧬 Livestock and poultry disease prevention and control and the landing of raw materials in multiple fields

The primary application of Tylvalosin tartrate is in swine disease control. Large-scale pig farms use it in feed to control endemic mycoplasma pneumonia, improving symptoms such as coughing, abdominal breathing, and growth retardation in affected pigs. Continuous dosing regimens control porcine proliferative ileitis induced by Lawsonia intracellularis, reducing persistent watery diarrhea and intestinal proliferative lesions. During PRRS outbreaks, its use in conjunction with other treatments can suppress viral load in pig herds, reducing widespread disease losses caused by secondary mycoplasma and bacterial pneumonia.

 

In poultry farming, it covers all breeds of chickens, including broilers, laying hens, and turkeys, preventing chronic respiratory diseases caused by Mycoplasma gallisepticum, Ornithobacter rhinotracheitis, and necrotic enteritis induced by Clostridium perfringens. It can be formulated as a water-soluble powder for drinking water administration to young poultry, or processed into a premix for long-term feed addition, mitigating respiratory and intestinal bacterial outbreaks associated with high-density poultry farming.

 

Veterinary drug manufacturers use high-purity Tylvalosin tartrate as the active ingredient to process it separately into 5% and 10% premixes and 20% water-soluble powders, or to combine it with raw materials of different mechanisms such as doxycycline and tilmicosin to develop broad-spectrum compound formulations. By leveraging complementary targets, they broaden the antibacterial spectrum and slow down the rate of bacterial resistance mutations induced by long-term use of single drugs.

High-purity raw materials are used in testing and research fields as content calibration standards for liquid chromatography and liquid chromatography-mass spectrometry (LC-MS) instruments to verify the content of active ingredients in commercially available veterinary drug formulations. They are also used for the quantitative detection of drug residues in feed and livestock meat products, meeting the food safety residue control testing requirements of livestock products in various countries.

 

Cutting-edge derivative applications revolve around human-related pharmacological exploration. Based on its established anti-inflammatory and apoptosis-regulating properties, it is used for basic research on inflammatory damage at the in vitro cellular level, exploring the potential development value of the molecule in non-veterinary fields and continuously expanding the application boundaries of the raw material.

🔭Formulation upgrades and application boundaries continue to expand

Globally, the focus of optimization efforts surrounding Tylvalosin tartrate is on developing novel drug delivery formulations. Addressing the limitations of the raw material's water solubility and the weak intestinal absorption in young livestock, processes for solid dispersions and nano-suspension water-soluble powders are gradually being implemented. These new formulations improve the raw material's dispersibility in water and intestinal absorption efficiency, further increasing the effective drug concentration in vivo at the same dosage and shortening the recovery period for sick livestock.

 

Refined management of drug resistance has become a routine optimization practice in the industry. Based on strain monitoring data, various regions are analyzing the drug resistance trends of Mycoplasma and Lawsonia in different farming areas, customizing rotational and combination dosing regimens, and using precise dosage control to reduce the pressure of drug selection, delay the widespread spread of drug-resistant strains, and ensure the long-term clinical effectiveness of the raw material.

 

The horizontal expansion of indications continues, with gradual optimization of efficacy for niche farmed animals such as dogs and sheep. The efficacy of the raw material in controlling Mycoplasma pneumonia in ruminants and respiratory bacterial infections in companion animals is being verified, and cross-species dosage and safety parameters are being improved to enrich the range of livestock and poultry for which the raw material is applicable.

 

Green synthesis processes have been iteratively optimized to replace traditional high-solvent-consumption routes. Continuous catalytic acylation reactions and low-temperature salt formation technologies are gradually being

implemented in industrial production lines, significantly reducing organic solvent waste discharge while simultaneously improving product purification yield and finished product purity. This aligns with global green production management standards for veterinary drugs and reduces the cost of industrial raw material production.

 

Drug repositioning research continues to deepen. Based on the clearly defined NF-κB pathway inhibition and anti-inflammatory activity, pharmacological exploration is ongoing around organ inflammatory injury models. The potential of molecules in anti-inflammatory sub-fields is being explored, expanding feasible pathways for APIs to extend from livestock and poultry drugs to pharmaceutical raw materials in multiple fields.

Conclusion

Tylvalosin tartrate, with its unique molecular structure of modified tylosin core and salted with tartaric acid, successfully breaks through the limitations of first-generation macrolides that can only inhibit bacteria in vitro. It achieves a triple pharmacological effect of antibacterial, antitoxic, and anti-inflammatory properties, occupying an irreplaceable raw material position in the prevention and control of respiratory and intracellular bacterial diseases in pigs and poultry. The diversification of formulations and the expansion of indications for multiple species continue to amplify the product's market value.

 

Pharmaceutical companies and wholesalers are welcome to visit Xi'an Faithful BioTech to learn about our commitment to the production and management of the Tylvalosin tartrate supply chain. Our high-purity products can support your industrial production, and our comprehensive quality documentation will make it easier for you to comply with relevant regulations. Please contact our experienced staff (allen@faithfulbio.com) to discuss your specific needs and explore business opportunities with this leading Tylvalosin tartrate manufacturer.

References

1. Guedes, R. M. C., França, S. A., Machado, G. S., Blumer, M. A., & Cruz, E. C. D. (2009). Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Veterinary Record, 165(12), 342–345.
2. Zhao, Z., Tang, X., Zhao, X., Zhang, M., Zhang, W., & Hou, S. (2014). Tylvalosin exhibits anti-inflammatory property and attenuates acute lung injury in different models possibly through suppression of NF-κB activation. Biochemical Pharmacology, 90(1), 73–87.
3. Moges, R., et al. (2018). Anti-Inflammatory Benefits of Antibiotics: Tylvalosin Induces Apoptosis of Porcine Neutrophils and Macrophages, Promotes Efferocytosis, and Inhibits Pro-Inflammatory CXCL-8, IL1α, and LTB4 Production. Frontiers in Veterinary Science, 5, 57.
4. Zhang, Q., et al. (2022). Tylvalosin Tartrate Improves the Health Status of Swine Herds during Immunization with Porcine Reproductive and Respiratory Syndrome Virus-Inactivated Vaccine. Veterinary Sciences, 10(1), 12.
5. Stuart, A. D., Brown, T. D. K., Imrie, G., Tasker, J. B., & Mockett, A. A. (2007). Intra-cellular accumulation and trans-epithelial transport of aivlosin, tylosin and tilmicosin. Pig Journal, 60, 26–35.
6. European Food Safety Authority. (2021). MRL assessment report for tylvalosin tartrate in food producing animals.
7. Mockett, A. P. A. (2008). Use of tylvalosin as antiviral agent. World Patent Publication, WO2008007104.